Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma

Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma

Abstract Background Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival. Methods We conduc...

Full description

Bibliographic Details
Main Authors: N. García-Romero, I. Palacín-Aliana, R. Madurga, J. Carrión-Navarro, S. Esteban-Rubio, B. Jiménez, A. Collazo, F. Pérez-Rodríguez, A. Ortiz de Mendivil, C. Fernández-Carballal, S. García-Duque, J. Diamantopoulos-Fernández, C. Belda-Iniesta, R. Prat-Acín, P. Sánchez-Gómez, E. Calvo, A. Ayuso-Sacido
Format: Article
Language:English
Published: BMC 2020-06-01
Series:BMC Medicine
Subjects:
VEGFA
Angiogenesis
Bevacizumab
Glioblastoma
Neovasculogenesis
Online Access:http://link.springer.com/article/10.1186/s12916-020-01610-0

Internet

http://link.springer.com/article/10.1186/s12916-020-01610-0

Similar Items